NCT06490341View on ClinicalTrials.gov

GP Combined With Nimotuzumab and Sintilimab as Induction Therapy for Nasopharyngeal Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 20, 2024

Primary Completion Date

July 20, 2026

Study Completion Date

July 20, 2027

Conditions
Locally Advanced Nasopharyngeal Carcinoma
Interventions
DRUG

GP Regimen, Nimotuzumab, Sintilimab

gemcitabine,ciplatin, nimotuzumab, sintilimab

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

NCT06490341 - GP Combined With Nimotuzumab and Sintilimab as Induction Therapy for Nasopharyngeal Carcinoma | Biotech Hunter | Biotech Hunter